Diabetes and cardiovascular diseases in type 2 diabetes from ukpds to steno 2
Download
1 / 49

Diabetes and Cardiovascular Diseases in Type 2 Diabetes: From UKPDS to Steno 2 - PowerPoint PPT Presentation


  • 91 Views
  • Uploaded on

Diabetes and Cardiovascular Diseases in Type 2 Diabetes: From UKPDS to Steno 2  . Dara P. Schuster, MD. Cardiovascular Disease. Early, aggressive interventions for risk reduction New, more effective therapies for treatment of HTN and hyperlipidemia

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Diabetes and Cardiovascular Diseases in Type 2 Diabetes: From UKPDS to Steno 2' - libitha


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Diabetes and cardiovascular diseases in type 2 diabetes from ukpds to steno 2

Diabetes and Cardiovascular Diseases in Type 2 Diabetes: From UKPDS to Steno 2 

Dara P. Schuster, MD


Cardiovascular disease
Cardiovascular Disease From UKPDS to Steno 2 

  • Early, aggressive interventions for risk reduction

  • New, more effective therapies for treatment of HTN and hyperlipidemia

  • Dramatic improvement in cardiovascular interventions

  • Marked reduction in smoking

Yet the increase in prevalence of obesity and diabetes is epidemic, with CVD the leading complication of DM



Powerpoint presentation scioto county medical society

The Metabolic Syndrome: Cardiac Care A Network of Atherogenic Factors

  • Glycemic disorders

  • Dyslipidemia

  • - Low HDL

  • - Small, dense LDL

  • Hypertriglyceridemia

  • Postprandial lipemia

  • Hypertension

  • Impaired thrombolysis

  • - PAI-1, fibrinogen

  • Endothelial dysfunction/

  • inflammation

  • - CRP, MMP-9, adiponectin

  • Microalbuminuria

Insulin

Resistance

 Free Fatty

Acids

VisceralObesity

Atherosclerosis

Brunzell J, Hokanson J. Diabetes Care. 1999;22(Suppl 3):C10-C13.

McFarlane S, et al. J Clin Endocrinol Metab. 2001;86(2):713-718.

Frohlich M, et al. Diabetes Care. 2000;23(12):1835-1839.

Kuusisto J, et al. Circulation. 1995;91:831-837.

Parulkar AA, et al. Ann Intern Med. 2001;134:61-71.

Hseuh WA, et al. Diabetes Care. 2001;24(2):392-397.

Lebovitz H. Clin Chem. 1999;45(8B):1339-1345.


Cardiovascular mortality associated with metabolic syndrome
Cardiovascular Mortality Associated Cardiac CareWith Metabolic Syndrome

p < 0.001

Diabetes Care 2001;24:683



Powerpoint presentation scioto county medical society

Obesity, Insulin Resistance and Endothelial Dysfunction Individual Components

FFA

IL-1

IL-6

PAI-1

TNF-

leptin

adiponectin

Obesity

CRP

FFA

TNF-

leptin

resistin

adiponectin

Endothelial

Dysfunction

Hyper-

insulinemia

Hyperglycemia

Hypertension

Dyslipidemia

Altered coag/fib

Insulin

Resistance

Caballero AE. Obes Res. 2003; 11: 1278-1289


Diabetes and heart failure current knowledge
Diabetes and Heart Failure: Individual ComponentsCurrent Knowledge




Stenting in diabetes clinical and angiographic outcomes
Stenting in Diabetes: Clinical Individual Componentsand Angiographic Outcomes

BARI – Mortality after CABG vs. PTCA, 2000


Powerpoint presentation scioto county medical society

BARI I: Individual Components Poorer Outcome with Revascularization in Diabetics

100

Non DM PTCA 86.8%

Non DM CABG 86.4%

DM CABG 76.4%

DM PTCA 55.7%

80

60

Percent Survival

40

Treatment Comparisons

Non-diabetics: p=0.72

Diabetics: p=0.0011

20

0

Years

0

1

2

3

4

5

6

7


Powerpoint presentation scioto county medical society

Revascularization in Diabetes: Individual Components

  • Co-morbidity (PVD , CRF )

  • Peri-procedural complications 

  • Worse long-term clinical outcomes

    • death, MI, stroke 

  • Excessive restenosis

    • intimal hyperplasia 

    • negative remodeling 

  • Accelerated atherosclerosis

    • progression of disease 

    • small vessel/diffuse disease 

BARI 2-D

All-cause mortality

CVD mortality & MI

Angina, employment

Retinopathy Neuropathy Nephropathy

PVD

HbA1c, BP, cholesterol

Cost-effectiveness


Blood glucose relates to mortality and risk for heart failure in mi
Blood Glucose Relates to Mortality Individual Componentsand Risk for Heart Failure in MI



Improved glycemic control has been shown to reduce the risk of complications
Improved Glycemic Control Has Been Shown to Reduce the Individual ComponentsRisk of Complications

According to the United Kingdom Prospective DiabetesStudy (UKPDS) 35, Every 1% Decrease in A1C Resulted in:

14%

12%

21%

37%

Decrease

in risk of microvascular

complications

(P<.0001)

Decrease in risk of any diabetes-related end point

(P<.0001)

Decrease in risk of stroke

(P=.04)

Decreasein risk of MI

(P<.0001)

Stratton IM et al. BMJ. 2000;321:405-412.


Ada standards of care
ADA Standards of Care Individual Components

  • ADA recommends a general A1C target of <7%

  • The goal of therapy for the individual patient is to achieve an A1C as close to normal (<6%) as possible without hypoglycemia

  • More stringent glycemic goals may reduce the risk of serious diabetes-related complications

  • Less stringent treatment goals may be appropriate for certain patient populations and patients with severe or more frequent hypoglycemia

American Diabetes Association. Diabetes Care. 2006;29:S4-S42.


The role of combination therapy in improving glycemic control aace recommendations
The Role of Combination Therapy in Improving Glycemic Control: AACE Recommendations

  • To reduce the risk of serious disease-related complications,1,2 AACE recommends:

    • Target A1C goal of ≤6.5%2,3

    • Intensive treatment of type 2 diabetes (i.e., earlier intervention with appropriate therapies and persistent titration to achieve goal)2,3

  • AACE recommends combining medications with different mechanisms of action to target multiple defects2,3

1. Stratton IM, et al. BMJ. 2000;321:405-412.

2. Davidson J, et al. Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement. July 8, 2005. Available at: http://www.aace.com/meetings/consensus/odimplementation/index.php. Accessed May 25, 2006.

3. Davidson J, et al. Road Map for the Prevention and Treatment of Type 2 Diabetes. 2005. Available at: http://www.aace.com/meetings/consensus/odimplementation/index.php. Accessed May 25, 2006.


The rationale for combination therapy multiple mechanisms of action targeting multiple sites

Skeletal Control: AACE RecommendationsMuscle

The Rationale for Combination Therapy:Multiple Mechanisms of Action Targeting Multiple Sites

Glucose

Increase Insulin Secretion in Functioning Pancreatic b-Cells2

Sulfonylureas/Secretagogues

PrimarilyDecreases Hepatic

Glucose Production*1

Liver

Insulin

Pancreas

Metformin

Adipose Tissue

Decrease Insulin Resistance

and Increase Peripheral

Glucose Uptake3

Thiazolidinediones

* Also decreases intestinal absorption of glucose and increases peripheral glucose uptake and utilization.

1. Glucophage [prescribing information]. Bristol-Myers Squibb.

2. Amaryl [prescribing information]. Aventis Pharmaceuticals.

3. AVANDIA® (rosiglitazone maleate) [prescribing information]. GlaxoSmithKline.


Effect of aspirin use on survival in patients with cad
Effect of Aspirin Use on Control: AACE RecommendationsSurvival in Patients With CAD


Syst eur reduction in event rate in adults 60 years with diabetes
Syst-Eur: Reduction in Event Rate in Adults ( Control: AACE Recommendations60 Years) With Diabetes



Mrfit impact of diabetes on cardiovascular disease mortality
MRFIT: Impact of Diabetes on SubgroupCardiovascular Disease Mortality






Hope outcomes in patients with diabetes
HOPE: Outcomes Diabetesin Patients With Diabetes


Bip b blocker treatment improves survival of patients with diabetes
BIP: Diabetes b-Blocker Treatment Improves Survival of Patients With Diabetes


Powerpoint presentation scioto county medical society

ACCORD Diabetes

First occurrence of a major cardiovascular disease event:

  • Nonfatal MI

  • Nonfatal Stroke

  • Cardiovascular Death

MI’s, Strokes, and Deaths adjudicated by a committee masked to treatment assignment


Powerpoint presentation scioto county medical society

Other ACCORD Outcomes Diabetes

  • Other cardiovascular outcomes

  • Total mortality

  • Microvascular outcomes

  • Health-related Quality of Life (subset)

  • Cost-effectiveness (subset)


Powerpoint presentation scioto county medical society

ACCORD Timeline Diabetes

1/03 Training

2/03 - 6/05 Recruit >8800 pts (30 months)

7/05 - 2/09 Follow-up (44 months)

3/09 - 6/09 Participant close-out (4 months)

7/09 - 3/10 Analysis & reporting (9 months)


Summary
Summary Diabetes


Summary cont
Summary, cont Diabetes


Dream diabetes reduction approaches with ramipril and rosiglitazone medications
DREAM: DiabetesDiabetes Reduction Approaches with ramipril and rosiglitazone Medications

  • Funded by King Pharmaceuticals, Aventis, SmithKline Beecham in conjunction with CIHR

  • F/U to the HOPE trial (heart outcomes prevention evaluation)

  • 5.5 year study

  • Rosiglitazone reduced the risk of Diabetes by 60%

  • Rosiglitazone had no effect on CVD outcome


Ukpds follow up
UKPDS Follow-up Diabetes

  • UKPDS 66 Patients with fatal MI had higher HbA(1c) than those with nonfatal MI (odds ratio 1.17 per 1% HbA(1c), P = 0.014). Patients with fatal stroke had higher HbA(1c) than those with nonfatal stroke (odds ratio 1.37 per 1% HbA(1c), P = 0.007). Stevens et. al. Diabetes care vol. 27, no. 1 (2004 Jan): 201-7.

  • High BP is detrimental to each aspect of diabetic retinopathy; a tight BP control policy reduces the risk of clinical complications from diabetic eye disease. Matthews DR, et. al.Archives of ophthalmology. vol. 122, no. 11 (2004 Nov): 1631-40


The need for early intervention
The Need for Early Intervention Diabetes

  • Norfolk Cohort (EPIC) – HbA1c predicted CVD

  • Nurses Health Study – CVD RR 3.17 before dx and 3.97 after dx.

  • Meta-analysis – progressive relationship between glu and CVD at levels below DM Dx

  • DECODE – glucose and CVD did not show a threshold effect (hazard ratios, IGT 1.1, 1.6 DM)

Khaw,et.al. BMJ 2001, 25. Hu et.al. Diabetes Care 2002:25. Coutinho et.al. Diabetes Care 1999:22. Decode study group Diabetes Care 2003:26.


Powerpoint presentation scioto county medical society
Earlier Addition of Rosiglitazone vs Uptitration of SU DiabetesRosiglitazone Added to SU Confers Durable Control Over 2 Years

Intent-to-Treat*

Completers†

Mean A1C(%)

Mean A1C(%)

0

0

Months

Months

* This is a repeated measures analysis accounting for baseline A1C, visit and treatment-visit interaction, and the correlation among visits within a patient. Baseline values reflect the average baseline A1C across all treatments as estimated using this model. All available values are utilized, including early visits from patients who subsequently withdrew from treatment. The A1C values at these early visits are reflected in estimated means for subsequent visits based on trends within each treatment.

† Data shown are for those subjects who completed the study without experiencing glycemic failure.

Data on file, GlaxoSmithKline.



Rosiglitazone treatment improves ldl particle density phenotype

Relative floatation (Rf) of Plasma (AIP)*

Rf <0.2632 (small dense)

Rf 0.2632 (large, more buoyant)

Rosiglitazone Treatment Improves LDL Particle Density Phenotype

100

80

70

55

60

45

Patients (%)

40

30

20

0

Pre-RSG

Week 8

Study 108. Data on file. GlaxoSmithKline.


Effect of pioglitazone on abdominal fat distribution
Effect of Pioglitazone on of Plasma (AIP)*Abdominal Fat Distribution


Brachial artery flow in igt and pvd before and 4 months after troglitazone therapy

Before occlusion of Plasma (AIP)*

700

700

*

After occlusion

*

600

600

500

500

*

*

400

400

*

300

300

200

200

100

100

0

0

Fasting

30 min

1 h

2 h

Fasting

30 min

1 h

2 h

Brachial Artery Flow in IGT and PVD Before and 4 Months After Troglitazone Therapy

Flow(mL/min)

Before therapy

After therapy

Avena R et al. J Vasc Surg. 1998;28:1024-1031.

*P<0.05 Before vs after occlusion (N=10).

©1999 PPS



Effects of thiazolidinediones on potential determinants of vasculopathy
Effects of Thiazolidinediones Carotid Artery IMT on Potential Determinants of Vasculopathy

Parameter Troglitazone Pioglitazone

PAI-1  in vivo  in vitro

Platelet aggregation  in vitro No effect in vitro

Intimal hyperplasia  in vivo  in vivo*

Smooth muscle cell proliferation/migration  in vitro  in vitro

Endothelial function  in vivo  in vitro*

*Experimental animal study

Marx N et al. Circ Res. 1998;83:1097-1103.

Minamikawa J et al. J Clin Endocrinol Metab. 1998;83:1818-1820.

Morikang E et al. Am J Hypertens. 1997;10:440-446.

Notoya Y et al. Diabetes. 1998;47:A365-366. Abstract.

Yamakawa K et al. Diabetes. 1998;47:A366. Abstract.

Avena R et al. J Vasc Surg. 1998;28:1024-1031.

Ehrmann DA et al. J Clin Endocrinol Metab. 1997;82:2108-2116.

Igarashi M et al. Horm Metab Res. 1997;29:444-449.

Ishizuka T et al. Diabetes. 1998;47:1494-1500.

Kotchen TA et al. Am J Physiol. 1996;270:R660-R666.

©1999 PPS


Effect of rosiglitazone on microalbuminuria
Effect Carotid Artery IMT of Rosiglitazone on Microalbuminuria


Powerpoint presentation scioto county medical society

Earlier Addition of Rosiglitazone vs Uptitration of SU Carotid Artery IMTSafety Profile Over a 2-Year Period

32%

27%

23%

10.3%

9%

9%

2.7%

3.4%

CardiacIschemia

Symptomatic Hypoglycemia

CHF

Edema

Rosenstock J, et al. Diabetes Obes Metab. 2006;8:49-57.

Data on file, GlaxoSmithKline.